Trusted Resource for Clinical Trials, Protocols & Progress
Protocol development isn’t just a medical writing exercise. Regulatory authorities like USFDA and EMA expect protocols to account for safety, statistical validity, ethical considerations, and execution feasibility. A cross-functional approach improves:
Click to read the full article.
Before drafting a pediatric protocol, review specific regulatory guidance such as:
Click to read the full article.
A protocol amendment is a formal, written change to a previously approved clinical trial protocol. Amendments may be classified as:
Click to read the full article.
Using a regulatory-endorsed protocol template ensures:
Click to read the full article.
A protocol synopsis is a concise summary of the essential components of the clinical trial protocol. It is typically one to two pages long and provides stakeholders — such as regulatory agencies, IRBs, and investigators — a quick reference to understand the trial design, objectives, and rationale.
Click to read the full article.
The protocol document lifecycle involves several stages: drafting, internal scientific review, cross-functional feedback, QC editing, final approval, and regulatory submission. Each stage has defined responsibilities and timelines to ensure quality and efficiency.
Click to read the full article.
The Investigator’s Brochure is a comprehensive document that consolidates all relevant clinical and nonclinical data on an investigational product. It is prepared by the sponsor and provided to investigators participating in clinical trials. It enables them to understand the rationale, risk profile, and safe handling of the product during trial conduct.
Click to read the full article.
Clinical trials inherently carry risk. The safety profile section enables investigators to:
Click to read the full article.
The IB is the cornerstone communication tool between the sponsor and clinical investigators. It serves to:
Click to read the full article.
The Investigator’s Brochure summarizes all relevant clinical and nonclinical data for an investigational product. As trials progress and new findings emerge, the IB must be amended to reflect:
Click to read the full article.
